Breaking News Instant updates and real-time market news.

AMRN

Amarin

$18.95

-1.06 (-5.30%)

, AZN

AstraZeneca

$49.85

-0.24 (-0.48%)

09:14
01/13/20
01/13
09:14
01/13/20
09:14

Amarin should rally on failure of two potential competitors, says Stifel

Stifel analyst Derek Archila expects shares of Amarin (AMRN) to be up today on news that AstraZeneca (AZN) discontinued Epanova's STRENGTH cardiovascular outcomes trial given the low likelihood it would demonstrate a cardiovascular benefit. While the STRENGTH study had a low probability of a positive outcome, its failure "no doubt reinforces the importance" of the pure eicosapentaenoic acid hypothesis and Vascepa's REDUCE-IT results, Archila tells investors in a research note. In addition, Acasti Pharma (ACST) reported that its Phase 3 TRILOGY 1 study results for its lead candidate, CaPre, in patients with hypertriglyceridemia failed, Archila points out. He notes that this program was also viewed as a potential competitor to Amarin's Vascepa. The analyst believes that with both of these failures, investor fears over near-to-medium term branded competition to Vaspeca should subside. Archila has a Hold rating on Amarin with a $28 price target. The stock in premarket trading is up 6% to $20.05.

AMRN

Amarin

$18.95

-1.06 (-5.30%)

AZN

AstraZeneca

$49.85

-0.24 (-0.48%)

ACST

Acasti Pharma

$2.20

-0.04 (-1.79%)

  • 13

    Jan

  • 13

    Jan

  • 13

    Jan

  • 06

    Feb

  • 13

    Feb

AMRN Amarin
$18.95

-1.06 (-5.30%)

01/10/20
ROTH
01/10/20
NO CHANGE
Target $31
ROTH
Buy
Amarin set up for strong partnership interest in the EU, says Roth Capital
Roth Capital analyst Yasmeen Rahimi says Amarin's continued news flow in early 2020, especially around approval of Vascepa by Health Canada and this week's continued strong guidance update, marks strong execution by the Amarin team as it keeps focused on U.S. commercialization in 2020. With a broad label in Canada that looks similar to FDA approval, Rahimi sees Amarin set up for strong partnership interest in the EU and remaining geographies. The analyst made no change to her Buy rating and $31 price target.
01/09/20
ROTH
01/09/20
NO CHANGE
Target $31
ROTH
Buy
Payers 'just need time' to update formularies for Amarin's Vascepa, Roth says
Following yesterday's speculation regarding UnitedHealth's (UNH) reimbursement of Amarin's (AMRN) Vascepa, Roth Capital analyst Yasmeen Rahimi believes payers "just need time to absorb label expansion to update formularies." Although Amarin communicated Vascepa's new label to all major payers within 24 hours of the recent approval, label expansion occurred barely four weeks ago and many payers are digesting specifics of the new label and how it impacts coverage, Rahimi tells investors in a research note tiled "World's the Oyster in 2020 for Vascepa." The analyst also notes that Amarin, per the company's management, already has meetings scheduled in Q1 with some of the largest national payers, "which should allow for productive dialogue especially around prior authorizations." Rahimi sees "strong supporting evidence" indicating that reimbursement and coverage will only improve given the new cardiovascular risk reduction label for Vascepa. With a "broad label" in Canada that looks similar to the FDA approval, Amarin is positioned for "strong partnership interest" in Europe and the remaining geographies, contends the analyst. Rahimi says the company's continued news flow in early 2020, especially around approval of Vascepa by Health Canada and this week's "continued strong" guidance update, marks strong execution by the management team. The analyst keeps a Buy rating on the shares with a $31 price target. Amarin in morning trading is up 70c to $20.16.
01/08/20
SBSH
01/08/20
NO CHANGE
SBSH
Neutral
Amarin selloff on UnitedHealth preferred list reports unwarranted, says Citi
Citi analyst Joel Beatty attributes the selloff today in shares of Amarin (AMRN) to reports stating that UnitedHealth (UNH) dropped Vascepa from its preferred list for 2020. However, after comparing 2019 and 2020 documents for a few UnitedHealth plans, Beatty did not find any examples of changes in tiering or other preferential status for Vascepa. Payers likely haven't yet considered the new "game-changing" cardiovascular risk-reduction label for Vascepa that was granted in December, which leaves Vascepa with no relevant competitors, Beatty tells investors in an intraday research note. As a result, the analyst, who keeps a Neutral rating on Amarin, views today's share pullback as unwarranted. The move creates a lower entry point for those investors looking to buy the stock, says Beatty. Amarin in afternoon trading is down 6%, or $1.15, to $18.93.
01/13/20
JPMS
01/13/20
NO CHANGE
JPMS
Epanova discontinuation positive for Amarin, says JPMorgan
JPMorgan analyst Jessica Fye views the removal of Epanova as a positive for Amarin (AMRN). AstraZeneca (AZN) said this morning that it is closing the Phase III trial for Epanova in mixed dyslipidaemia following the recommendation from an independent Data Monitoring Committee. Epanova is an omega-3 carboxylic acid and was being studied to demonstrate a possible benefit in patients with mixed dyslipidaemia who are at increased risk of cardiovascular disease. Shares of Amarin are up 6%, or $1.07, to $20.02 in premarket trading.
AZN AstraZeneca
$49.85

-0.24 (-0.48%)

12/26/19
STFL
12/26/19
NO CHANGE
Target $180
STFL
Buy
Stifel sees path to $230 for Iqvia shares after 'significant' AstraZeneca win
Stifel analyst Shlomo Rosenbaum views AstraZeneca (AZN) selecting the Orchestrated Customer Engagement platform as a "significant win" for Iqvia Holdings (IQV). The deal is a takeaway from Veeva (VEEV), is for all of AstraZeneca in the U.S., and has the potential for upsizing both through global expansion and additional modules, Rosenbaum tells investors in a research note. The analyst continues to like the Iqvia story and sees a valuation path in the $230s range in the next several years as the story plays out. Iqvia closed Tuesday down 17c to $154.70. Rosenbaum has a Buy rating on the name with a $180 price target.
12/19/19
KEYB
12/19/19
NO CHANGE
KEYB
Iqvia win at AstraZeneca at loss for Veeva, says KeyBanc
KeyBanc analyst Donald Hooker said Iqvia's (IQV) announcement that AstraZeneca (AZN) will be fully deploying its Orchestrated Customer Engagement platform in the U.S. "is reportedly a direct rip-and-replacement of competitor and market share leader" Veeva Systems (VEEV), adding that Iqvia's hopes to further displace Veeva by expand its OCE relationship with Astra outside of the U.S. Iqvia disclosed 20 new OCE wins in Q3, 15 of which were reportedly head-to-head wins against Veeva and 2 of which were direct displacements, add Hooker. He has a Sector Weight rating on Iqvia shares.
12/19/19
BARD
12/19/19
NO CHANGE
BARD
Outperform
AstraZeneca deal a 'landmark win' for Iqvia OCE solution, says Baird
Baird analyst Eric Coldwell called Iqvia's (IQV) commitment from AstraZeneca (AZN) to rollout the company's Orchestrated Customer Engagement, or OCE, solution to the company's specialized medicines group in the U.S., which could represent over 5,000 total licenses, a "landmark win" for the offering. He also said it could unfavorably impact shares of competitor Veeva (VEEV). AstraZeneca has about 30,000 sales reps globally and Iqvia expects to compete for the global business, assuming a good U.S. rollout, added Coldwell, who keeps an Outperform rating on the stock. In early afternoon trading, Iqvia shares are up 1% to $148.74 while Veeva has slid nearly 4% to $139.04.
ACST Acasti Pharma
$2.20

-0.04 (-1.79%)

12/24/19
RILY
12/24/19
NO CHANGE
Target $8
RILY
Buy
B. Riley FBR continues to like Acasti Pharma risk-reward going into 2020
B. Riley FBR analyst Mayank Mamtani notes that Acasti Pharma issued a press release disclosing a small delay in reporting Phase III TRILOGY 1 pivotal top-line data for the company's leading omega-3 phospholipid drug candidate, CaPre, for the 12-week treatment of severe hypertriglyceridemia patients i.e., from original guidance of year end to January 2020. The analyst acknowledges study delays are cautiously viewed by investors. However, Mamtani believes this to have absolutely no relevance to the anticipated clinical study results including likelihood of technical and regulatory success and effect size noted in the trial determining commercial success in the overall triglyceride lowering marketplace. The analyst continues to like the risk-reward noting substantial upside in his basecase assumption of TRILOGY studies hitting statistical significance on the primary endpoint TG's reduction of 20%. Mamtani reiterates a Buy rating and $8 price target on the shares.
08/29/19
RILY
08/29/19
INITIATION
Target $7.75
RILY
Buy
Acasti Pharma initiated with a Buy at B. Riley FBR
B. Riley FBR analyst George Zavoico earlier today initiated coverage of Acasti Pharma with a Buy rating and $7.75 price target. The stock in early trading is up 7% to $1.83. The analyst expects positive Phase III results in early Q1 of 2020 for the company's leading drug candidate, CaPre. CaPre is indicated for adverse cardiovascular event risk reduction in patients with elevated levels of certain lipids, a big market of ~80M Americans, Zavoico tells investors in a research note. He believes CaPre could be the best-in-class omega-3 fatty acid drug and could capture a large share of the market. He also expects a capital raise by Acasti or partnership agreement later this year or early in 2020.
01/13/20
RILY
01/13/20
DOWNGRADE
Target $2
RILY
Neutral
Acasti Pharma downgraded to Neutral from Buy at B. Riley FBR
B. Riley FBR analyst Mayank Mamtani downgraded Acasti Pharma to Neutral from Buy with a $2 price target.
07/18/19
07/18/19
INITIATION
Target $7

Outperform
Oppenheimer bullish on Acasti Pharma, initiates with an Outperform
As previously reported, Oppenheimer analyst Leland Gershell started coverage of Acasti Pharma (ACST) with an Outperform rating and $7 price target. While the analyst notes that Vascepa's prospects to serve a multibillion-dollar sales opportunity have driven significant value appreciation for Amarin (AMRN), he believes Acasti Pharma's potentially best-in-class omega-3 is only months away from pivotal readouts in the very high triglycerides niche, and anticipates a REDUCE-IT-like label expansion can be secured without new outcomes data. With shares trading at just a about $100M EV, Gershell believes Acasti holds "considerable upside" as CaPre approaches commercialization, its advantages are better appreciated, and Vascepa's sales growth continues to impress.

TODAY'S FREE FLY STORIES

TLGT

Teligent

$0.40

-0.0025 (-0.62%)

15:53
01/18/20
01/18
15:53
01/18/20
15:53
Conference/Events
Teligent to hold a special shareholder meeting »

Special Shareholder…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 24

    Jan

AYTU

Aytu BioScience

$0.80

0.0014 (0.18%)

15:48
01/18/20
01/18
15:48
01/18/20
15:48
Conference/Events
Aytu BioScience to hold a special shareholder meeting »

Special Shareholder…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 24

    Jan

DVA

DaVita

$79.45

0.43 (0.54%)

15:32
01/18/20
01/18
15:32
01/18/20
15:32
Conference/Events
DaVita to host special shareholder meeting »

Special Shareholder…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 23

    Jan

TSM

TSMC

$58.58

-0.18 (-0.31%)

09:16
01/18/20
01/18
09:16
01/18/20
09:16
Periodicals
Taiwan tech stocks can ignore China's bluster for now, Barron's says »

China's government…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

KKR

KKR

$31.20

0.7 (2.30%)

, APO

Apollo Global

$50.35

1.26 (2.57%)

09:03
01/18/20
01/18
09:03
01/18/20
09:03
Periodicals
KKR undervalued compared with peers, Barron's says »

KKR (KKR) gained 50% last…

KKR

KKR

$31.20

0.7 (2.30%)

APO

Apollo Global

$50.35

1.26 (2.57%)

ARES

Ares Management

$37.29

0.47 (1.28%)

BX

Blackstone

$60.79

0.62 (1.03%)

CG

Carlyle Group

$33.30

0.36 (1.09%)

HLNE

Hamilton Lane

$67.25

-0.02 (-0.03%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 30

    Jan

  • 30

    Jan

  • 31

    Jan

  • 31

    Jan

  • 04

    Feb

  • 04

    Feb

  • 05

    Feb

  • 13

    Feb

  • 17

    Feb

  • 26

    Feb

SPCE

Virgin Galactic

$15.65

0.685 (4.58%)

, TWNK

Hostess Brands

$14.03

0.02 (0.14%)

08:56
01/18/20
01/18
08:56
01/18/20
08:56
Periodicals
'Blank-check' companies hot on Wall Street, Barron's says »

More than a quarter of…

SPCE

Virgin Galactic

$15.65

0.685 (4.58%)

TWNK

Hostess Brands

$14.03

0.02 (0.14%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 25

    Feb

  • 04

    Mar

GOOG

Alphabet

$1,480.28

28.34 (1.95%)

, NFLX

Netflix

$339.56

0.89 (0.26%)

08:47
01/18/20
01/18
08:47
01/18/20
08:47
Periodicals
Peacock's pricing might be 'killer feature,' Barron's says »

This week, Peacock…

GOOG

Alphabet

$1,480.28

28.34 (1.95%)

NFLX

Netflix

$339.56

0.89 (0.26%)

CMCSK

Comcast

$0.00

(0.00%)

CMCSA

Comcast

$47.48

0.62 (1.32%)

GOOGL

Alphabet Class A

$1,479.12

29.29 (2.02%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 21

    Jan

  • 22

    Jan

  • 23

    Jan

  • 03

    Feb

  • 03

    Feb

  • 10

    Feb

JWN

Nordstrom

$40.34

-0.15 (-0.37%)

, WMT

Walmart

$114.93

-0.96 (-0.83%)

08:36
01/18/20
01/18
08:36
01/18/20
08:36
Periodicals
Casper IPO highlights tech's promise, troubles, Barron' says »

Mattresses have been…

JWN

Nordstrom

$40.34

-0.15 (-0.37%)

WMT

Walmart

$114.93

-0.96 (-0.83%)

CSPR

Casper Sleep

$0.00

(0.00%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 21

    Jan

  • 18

    Feb

BA

Boeing

$324.11

-7.89 (-2.38%)

, DDAIF

Daimler AG

$0.00

(0.00%)

08:12
01/18/20
01/18
08:12
01/18/20
08:12
On The Fly
Week in Review: How Trump's policies moved stocks »

Catch up on the top…

BA

Boeing

$324.11

-7.89 (-2.38%)

DDAIF

Daimler AG

$0.00

(0.00%)

FCAU

Fiat Chrysler

$13.76

-0.14 (-1.01%)

VWAGY

Volkswagen

$0.00

(0.00%)

FSLR

First Solar

$53.51

-0.42 (-0.78%)

AAPL

Apple

$318.66

3.33 (1.06%)

DQ

Daqo New Energy

$53.61

-0.025 (-0.05%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 28

    Jan

  • 29

    Jan

SPOT

Spotify

$148.20

-3.59 (-2.37%)

18:15
01/17/20
01/17
18:15
01/17/20
18:15
Periodicals
Spotify in talks to acquire The Ringer, WSJ reports »

Spotify is in discussions…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 05

    Feb

CE

Celanese

$117.54

-0.53 (-0.45%)

18:00
01/17/20
01/17
18:00
01/17/20
18:00
Hot Stocks
Celanese announces acetyl intermediates price increases »

Celanese Corporation will…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 31

    Jan

BYND

Beyond Meat

$109.20

-1.16 (-1.05%)

17:58
01/17/20
01/17
17:58
01/17/20
17:58
Periodicals
Beyond Meat rival gets green light in Canada, The Star says »

Impossible Foods, a maker…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

DBD

Diebold

$11.09

-0.49 (-4.23%)

17:42
01/17/20
01/17
17:42
01/17/20
17:42
Periodicals
Breaking Periodicals news story on Diebold »

Diebold Nixdorf divests…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

IEF

iShares 7-10 Year Treasury Bond ETF

$111.28

-0.13 (-0.12%)

, SHY

iShares 1-3 Year Treasury Bond

$84.73

-0.005 (-0.01%)

17:32
01/17/20
01/17
17:32
01/17/20
17:32
General news
Weekly CFTC Commitment of Traders highlights »

2-YEAR U.S. TREASURY net…

IEF

iShares 7-10 Year Treasury Bond ETF

$111.28

-0.13 (-0.12%)

SHY

iShares 1-3 Year Treasury Bond

$84.73

-0.005 (-0.01%)

SPY

SPDR S&P 500 ETF Trust

$331.98

1.08 (0.33%)

SLV

iShares Silver Trust

$16.82

0.04 (0.24%)

GLD

SPDR Gold Shares

$146.59

0.29 (0.20%)

FXE

Euro Currency Trust

$105.10

-0.43 (-0.41%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

UBSFY

Ubisoft

$0.00

(0.00%)

17:32
01/17/20
01/17
17:32
01/17/20
17:32
Periodicals
Ubisoft to restructure editorial team after difficult 2019, VGC reports »

Ubisoft intends to…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 17

    Jan

  • 18

    Feb

IMVT

Immunovant

$17.04

-0.01 (-0.06%)

17:27
01/17/20
01/17
17:27
01/17/20
17:27
Syndicate
Breaking Syndicate news story on Immunovant »

Immunovant files to sell…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

TBLT

ToughBuilt

$0.33

-0.0255 (-7.11%)

17:20
01/17/20
01/17
17:20
01/17/20
17:20
Syndicate
ToughBuilt files to sell common stock, no amount given »

Maxim acted as sole book…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

MYO

Myomo

$0.32

0.0062 (1.98%)

17:18
01/17/20
01/17
17:18
01/17/20
17:18
Conference/Events
Myomo to host special shareholder meeting »

Special Shareholder…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 21

    Jan

SRRA

Sierra Oncology

$0.40

-0.02 (-4.76%)

17:14
01/17/20
01/17
17:14
01/17/20
17:14
Conference/Events
Sierra Oncology to host virtual special shareholder meeting »

Virtual Special…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 21

    Jan

SRNE

Sorrento Therapeutics

$4.26

-0.15 (-3.40%)

17:10
01/17/20
01/17
17:10
01/17/20
17:10
Syndicate
Breaking Syndicate news story on Sorrento Therapeutics »

Sorrento Therapeutics…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

AKER

Akers Biosciences

$3.45

-0.1 (-2.82%)

17:01
01/17/20
01/17
17:01
01/17/20
17:01
Hot Stocks
Akers Biosciences reaches settlement agreements on two derivative actions »

Akers Biosciences…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

ECA

Encana

$4.09

-0.18 (-4.22%)

16:40
01/17/20
01/17
16:40
01/17/20
16:40
Hot Stocks
Encana receives court approval for reorganization »

Encana Corporation…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 29

    Jan

MBRX

Moleculin Biotech

$0.96

0.0122 (1.29%)

16:38
01/17/20
01/17
16:38
01/17/20
16:38
Syndicate
Breaking Syndicate news story on Moleculin Biotech »

Moleculin Biotech files…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

VOD

Vodafone

$20.07

-0.225 (-1.11%)

, BT

BT Group

$0.00

(0.00%)

16:37
01/17/20
01/17
16:37
01/17/20
16:37
Periodicals
BT, Vodafone consider urging PM Johnson not to ban Huawei in U.K., Reuters says »

BT Group (BT) and…

VOD

Vodafone

$20.07

-0.225 (-1.11%)

BT

BT Group

$0.00

(0.00%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

16:30
01/17/20
01/17
16:30
01/17/20
16:30
Options
Preliminary option volume of 28.7M today »

Preliminary option volume…

Get Full Fly Access

Breaking market intelligence sent straight to you
Our team of experts analyze every news story and filter out the noise to deliver real-time market moving news.
Up-to-date information on important industry events
Get real-time updates on events that are moving the market—from conferences and calls to syndicate announcements.
News focused on the companies in your portfolio
Create up to 12 portfolios with 150 stocks each, and see how active they are in market news.